SSY Group Ltd. announced that it has received approval from the National Medical Products Administration of China for the production and registration of Propafenone Hydrochloride Injection (20ml:70mg). This product, classified as a type 3 chemical drug, has passed the consistency evaluation and marks the third such approval for PRC entities. Propafenone Hydrochloride Injection is primarily used for the treatment of supraventricular tachycardia, including atrioventricular junctional tachycardia, WPW syndrome with supraventricular tachycardia, paroxysmal atrial fibrillation, and ventricular tachycardia requiring treatment or life-threatening situations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260130-12005523), on January 30, 2026, and is solely responsible for the information contained therein.